| MeSH term | MeSH ID | Detail |
|---|---|---|
| Adenocarcinoma | D000230 | 166 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Candidiasis, Oral | D002180 | 11 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Edema | D004487 | 152 associated lipids |
| Fibrosis | D005355 | 23 associated lipids |
| Glioblastoma | D005909 | 27 associated lipids |
| Glioma | D005910 | 112 associated lipids |
| Carcinoma, Hepatocellular | D006528 | 140 associated lipids |
(e,z)-farnesol
(e,z)-farnesol is a lipid of Prenol Lipids (PR) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 3613 references associated with (e,z)-farnesol in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for (e,z)-farnesol
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with (e,z)-farnesol
PubChem Biomolecular Interactions and Pathways
All references with (e,z)-farnesol
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Supuran CT | Nanoparticles for controlled release of anti-biofilm agents WO2014130994 (A1): a patent evaluation. | 2015 | Expert Opin Ther Pat | pmid:26028186 |
| Rosales A et al. | Synthesis of (±)-aureol by bioinspired rearrangements. | 2015 | J. Org. Chem. | pmid:25591135 |
| Brilhante RS et al. | Histoplasma capsulatum in planktonic and biofilm forms: in vitro susceptibility to amphotericin B, itraconazole and farnesol. | 2015 | J. Med. Microbiol. | pmid:25657300 |
| Abdel-Rhman SH et al. | Effect of Tyrosol and Farnesol on Virulence and Antibiotic Resistance of Clinical Isolates of Pseudomonas aeruginosa. | 2015 | Biomed Res Int | pmid:26844228 |
| Joo JH et al. | Farnesol activates the intrinsic pathway of apoptosis and the ATF4-ATF3-CHOP cascade of ER stress in human T lymphoblastic leukemia Molt4 cells. | 2015 | Biochem. Pharmacol. | pmid:26275811 |
| Krause J et al. | Prostaglandin E2 from Candida albicans Stimulates the Growth of Staphylococcus aureus in Mixed Biofilms. | 2015 | PLoS ONE | pmid:26262843 |
| Mogen AB et al. | Pluronics-Formulated Farnesol Promotes Efficient Killing and Demonstrates Novel Interactions with Streptococcus mutans Biofilms. | 2015 | PLoS ONE | pmid:26222384 |
| Hargarten JC et al. | Candida albicans Quorum Sensing Molecules Stimulate Mouse Macrophage Migration. | 2015 | Infect. Immun. | pmid:26195556 |
| Stoddart CA et al. | Oral administration of the nucleoside EFdA (4'-ethynyl-2-fluoro-2'-deoxyadenosine) provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaque. | 2015 | Antimicrob. Agents Chemother. | pmid:25941222 |
| de Salas F et al. | Quorum-Sensing Mechanisms Mediated by Farnesol in Ophiostoma piceae: Effect on Secretion of Sterol Esterase. | 2015 | Appl. Environ. Microbiol. | pmid:25888179 |
| Badar T et al. | Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies. | 2015 | Clin Lymphoma Myeloma Leuk | pmid:25795639 |
| Zhang W et al. | Vaginal Microbicide Film Combinations of Two Reverse Transcriptase Inhibitors, EFdA and CSIC, for the Prevention of HIV-1 Sexual Transmission. | 2015 | Pharm. Res. | pmid:25794967 |
| Leonhardt I et al. | The fungal quorum-sensing molecule farnesol activates innate immune cells but suppresses cellular adaptive immunity. | 2015 | MBio | pmid:25784697 |
| Horev B et al. | pH-activated nanoparticles for controlled topical delivery of farnesol to disrupt oral biofilm virulence. | 2015 | ACS Nano | pmid:25661192 |
| De Loof A | The essence of female-male physiological dimorphism: differential Ca2+-homeostasis enabled by the interplay between farnesol-like endogenous sesquiterpenoids and sex-steroids? The Calcigender paradigm. | 2015 | Gen. Comp. Endocrinol. | pmid:25540913 |
| Léger T et al. | The metacaspase (Mca1p) has a dual role in farnesol-induced apoptosis in Candida albicans. | 2015 | Mol. Cell Proteomics | pmid:25348831 |
| Katragkou A et al. | In vitro interactions between farnesol and fluconazole, amphotericin B or micafungin against Candida albicans biofilms. | 2015 | J. Antimicrob. Chemother. | pmid:25288679 |
| Scheman A et al. | European Directive fragrances in natural products. | 2014 Mar-Apr | Dermatitis | pmid:24603515 |
| Sakane C et al. | Inhibition of lysine-specific demethylase 1 by the acyclic diterpenoid geranylgeranoic acid and its derivatives. | 2014 | Biochem. Biophys. Res. Commun. | pmid:24406160 |
| Ling Y et al. | Synthesis and biological evaluation of farnesylthiosalicylamides as potential anti-tumor agents. | 2014 | Bioorg. Med. Chem. | pmid:24300920 |